Journal article
An activation-specific platelet inhibitor that can be turned on/off by medically used hypothermia
D Topcic, W Kim, JK Holien, F Jia, PC Armstrong, JD Hohmann, A Straub, G Krippner, CA Haller, H Domeij, CE Hagemeyer, MW Parker, EL Chaikof, K Peter
Arteriosclerosis Thrombosis and Vascular Biology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2011
Abstract
Objective-: Therapeutic hypothermia is successfully used, for example, in cardiac surgery to protect organs from ischemia. Cardiosurgical procedures, especially in combination with extracorporeal circulation, and hypothermia itself are potentially prothrombotic. Despite the obvious need, the long half-life of antiplatelet drugs and thus the risk of postoperative bleedings have restricted their use in cardiac surgery. We describe here the design and testing of a unique recombinant hypothermia-controlled antiplatelet fusion protein with the aim of providing increased safety of hypothermia, as well as cardiac surgery. Methods and results-: An elastin-mimetic polypeptide was fused to an activati..
View full abstractGrants
Funding Acknowledgements
This work was funded by the National Health and Medical Research Council (NHMRC) and National Heart Foundation of Australia. Dr Parker is an Australian Research Council Federation Fellow and NHMRC Honorary Fellow. Dr Peter is an Australian Research Council Future Fellow and NHMRC Honorary Fellow.